Jung-Mo Ahn

Associate Professor - Chemistry
jungmo.ahn@utdallas.edu
972-883-2917
BSB 11.538
UTD Webpage
ORCID
Tags: Biochemistry and Chemical Biology Organic Bio-Organic Medicinal

Professional Preparation

Postdoctoral Associate
The Scripps Research Institute - 2004
Ph.D. - Chemistry
University of Arizona - 2000
M.S.
Seoul National University - 1994
B.S.
Seoul National University - 1992

Research Areas

Research Description
The central theme of my research is to understand the chemistry and biology of peptides and proteins and to develop new approaches for manipulating these properties with purposefully designed small organic molecules. We employ chemical synthesis and combinatorial chemistry as well as spectroscopic and biophysical methods to accomplish these aims. Projects include:

  • Rational design of small organic molecules for mimicking protein secondary structures
  • Inhibition of key protein-protein interactions in various cancer models 

Publications

Development of Potent Glucagon Antagonists: Structure-Activity Relationship Study of Glycine at Position 4 2001 - Journal Article
Development of Potent Truncated Glucagon Antagonists 2001 - Journal Article
The Design and Biological Activities of Glucagon Agonists and Antagonists, and Their Use in Examining the Mechanisms of Glucose Action 2001 - Journal Article
Design and Synthesis of Conformationally Constrained Glucagon Analogues 2000 - Journal Article
Structure-Function Studies on Positions 17, 18, and 21 Replacement Analogues of Glucagon: The Importance of Charged Residues and Salt Bridges in Glucagon Biological Activity 1998 - Journal Article
Synthesis of Oligopeptide and Peptidomimetic Libraries 1997 - Journal Article
The Role of Phenylalanine at Position 6 in Glucagon’s Mechanim of Biological Action: Multiple Replacement Analogues of Glucagon 1997 - Journal Article

Awards

Thieme Chemistry Journal Award - Thieme Verlag [2011]
Siemens Preclinical Image of the Year - World Congress of Molecular Imaging [2010]
Junior Faculty Award - American Diabetes Association [2007]
Bruce W. Erickson Young Investigator’s Award - American Peptide Society [2001]
Mid-Career Fellowship, American Chemical Society - American Chemical Society [1996]

News Articles

UT Dallas Chemist Focuses on Drug-Resistant Breast Cancer
Dr. Jung-Mo Ahn, associate professor of chemistry and biochemistry at The University of Texas at Dallas, has designed a small molecule that could help breast cancer patients for whom current treatments no longer work.  In a paper published recently in the online journal eLife, Ahn and his colleagues describe their approach to designing the molecule as well as experiments that show its effectiveness at stopping the progression of treatment-resistant breast cancer cells in isolation and in an animal model.  According to the National Cancer Institute, about 80 percent of breast cancers in women depend on the hormone estrogen to grow. Breast cancer cells in these patients contain proteins called estrogen receptors (ERs) that bind to the hormone and fuel cancer’s growth.  For these ER-positive patients, treatment typically takes one of two tracks: drug regimens that stifle the body’s production of estrogen, or drugs that bind to estrogen receptors and block the hormone from attaching.  In some patients, however, breast cancer becomes resistant to estrogen-blocking therapy. That happens when estrogen receptors in breast cancer cells mutate and change shape, leaving no place for the drugs to attach. With or without genetic mutations, the receptor still needs to recruit other proteins in the cell, called co-regulators, which promote tumor growth.  “Upon estrogen binding, estrogen receptors interact with other proteins like co-regulators to stimulate cancer cell growth,” Ahn said. “Blocking these co-regulators is a new mode of action that could overcome treatment barriers.”

Small Molecule Could Have Big Impact on Prostate Cancer
Dr. Jung-Mo Ahn, associate professor of chemistry at The University of Texas at Dallas, has designed and synthesized a novel, small molecule that might become a large weapon in the fight against prostate cancer. In a study published online May 28 in the journal Nature Communications, Ahn and his colleagues at UT Southwestern Medical Center describe the design of the molecule, as well as laboratory tests that show its effectiveness at blocking the cancer-promoting function of proteins called androgen receptors. Androgen receptors are found inside cells and have complex surfaces with multiple “docking points,” where various proteins can bind to the receptor. Each docking point has a unique shape, so only a correctly shaped molecule will fit.
Researcher Lands Grant from Texas Cancer Initiative
Molecules that attempt to trick cancer cells into killing themselves off are the latest weapons being tested to wage and win the war on cancer. The Cancer Prevention and Research Institute of Texas (CPRIT) has awarded $886,000 to Dr. Jung-Mo Ahn to study a new class of molecules designed to wring the life out of prostate cancer cells. Ahn, an assistant professor of chemistry, is testing compounds called tris-benzamides. Tris-benzamides may coax cancer cells into behaving like normal cells, which eventually allow themselves to die in a process called apoptosis, or programmed cell death. “Cancer cells bypass apoptosis by overproducing anti-apoptotic proteins that block the cells from dying, so they live on and wreak havoc in the body,” Ahn said. “Our tris-benzamides are specially designed to lock into the surface of anti-apoptotic proteins. It gives cancer cells a wake-up call that it’s time to die off.”